As August approaches, it's time for our regular review of the critical FDA decisions on the horizon.
So far this year, 22 novel drugs have been approved by the FDA compared to 29 during the same period last year. ("Novel" drugs are new drugs never before approved or marketed in the U.S.: Source: FDA).
Separately, August is observed as spinal muscular atrophy (SMA) awareness month. SMA is a rare genetic neurodegenerative disorder characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness.
Typically, fatal and commonly diagnosed in young children, SMA has no complete cure. However, approved therapies can manage the symptoms of this neuromuscular disease. Notable treatments include Biogen's Spinraza, Novartis' Zolgensma, and Roche's Evrysdi.
FDA decisions can make or break biotech stocks. Stay ahead of the market by accessing detailed insights and analysis. Don't miss out on these potential game-changers.
Click here now to uncover the biotech stocks poised for action this August!
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.